Christine L Kempton
Affiliation: Emory University
- How we treat a hemophilia A patient with a factor VIII inhibitorChristine L Kempton
Aflac Cancer Center and Blood Disorders Service and Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA
Blood 113:11-7. 2009..Ideally, prediction and ultimately prevention will come with an improved understanding of how patient-specific and treatment-related factors work together to influence anti-factor VIII antibody production...
- Inhibitors in previously treated patients: a review of the literatureC L Kempton
Aflac Cancer Center and Blood Disorders Service and Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA 30322, USA
Haemophilia 16:61-5. 2010..This review will discuss the published literature on epidemiology and clinical characteristics of inhibitors and possible risk factors for formation in PTPs...
- In non-severe hemophilia A the risk of inhibitor after intensive factor treatment is greater in older patients: a case-control studyC L Kempton
Aflac Cancer Center and Blood Disorders Service and Department of Hematology and Medical Oncology, Emory University, Atlanta, GA, USA
J Thromb Haemost 8:2224-31. 2010..Although intensive FVIII treatment has long been considered a risk factor for inhibitor development in those with non-severe disease, its strength of association and the influence of other factors have remained undefined...
- Eradication of factor VIII inhibitors in patients with mild and moderate hemophilia AChristine L Kempton
Emory University, Atlanta, Georgia 30322, USA
Am J Hematol 87:933-6. 2012..4 (95% CI = 1.06–20.03) and 10.21 (95% CI = 1.17–78.28), respectively], whereas ITI alone (n = 9) was not [HR = 1.35 (95% CI = 0.44–4.07)]...
- Factor VIII A3 domain substitution N1922S results in hemophilia A due to domain-specific misfolding and hyposecretion of functional proteinRyan J Summers
Emory University School of Medicine, Atlanta, GA, USA
Blood 117:3190-8. 2011....